About
Small molecule discovery
Areas of Focus
Categories
Small Molecule PharmaceuticalSan Diego & Southern California
Team (11)
Andrew Dorr, M.D.
Orphagen Pharmaceuticals
team_member
Anjana Rao, Ph.D.
Orphagen Pharmaceuticals
team_member
Casey T. Weaver, M.D.
Orphagen Pharmaceuticals
team_member
Gary Hammer, M.D. Ph.D.
Orphagen Pharmaceuticals
team_member
JoAnn Z. Wilson, Ph.D.
Orphagen Pharmaceuticals
team_member
Jukka Muhonen, MBA, LL.M.
Orphagen Pharmaceuticals
team_member
Clinical Trials (19)
View allTotal Trials
19
As Lead Sponsor
16
As Collaborator
3
Total Enrollment
1,655
By Phase
PHASE3: 9PHASE4: 1PHASE2: 3PHASE1: 3PHASE1/PHASE2: 2
By Status
COMPLETED: 14RECRUITING: 2ENROLLING_BY_INVITATION: 1ACTIVE_NOT_RECRUITING: 1WITHDRAWN: 1
Clinical Trials Pipeline19 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Today
Hover over trial bars to see details
Recent Trials
NCT06350032Lead Sponsor
Investigational Trial to Evaluate Safety and Tolerability of Treprostinil in Children Diagnosed With PAH
PHASE3Recruiting
20 participants
Started: Jul 31, 2024 · Completed: Nov 30, 2028
NCT06445673Lead Sponsor
A Prospective Non-interventional Observational Study to Observe Long-term Treatment and Outcomes in Pulmonary Arterial Hypertension (PAH) Patients
N/AEnrolling by invitation
110 participants
Started: Jul 31, 2024 · Completed: Jun 30, 2030
NCT06317805Lead Sponsor
Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients
PHASE4Recruiting
110 participants
Started: Dec 6, 2023 · Completed: Jun 30, 2027
NCT06514807Lead Sponsor
A Study to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythaemia Patients
PHASE3Active, not recruiting
117 participants
Started: Dec 4, 2023 · Completed: Mar 15, 2028
NCT03117816Collaborator
ENDURE - Efficacy and Safety of AOP2014 With CML Patients in Remission
PHASE3Completed
214 participants
Started: May 4, 2017 · Completed: Dec 12, 2022
Locations (1)
Headquarters
San Diego, CA, United States
Map
Loading map...